Investigation of Treatment-Related Disparities in Metastatic Pancreatic Cancer Patients Using Real-World Data.

ABSTRACT:

Background

Racial disparities exist in the overall treatment of patients with metastatic pancreatic adenocarcinoma (mPDAC). Compared to White patients, patients of color are less likely to undergo surgical resection for early-stage disease and receive chemotherapy. This study explored the time to first treatment (T2FT), receipt of standard guideline-concordant first-line therapies, and overall survival in an mPDAC population by race/ethnicity.

Methods

Utilizing real-world United States data from the Flatiron Health electronic health record (EHR) derived, deidentified database, T2FT was defined as the difference between the diagnosis date of mPDAC and the initiation of first-line systemic anticancer therapy in days; receipt of standard-guideline concordant first-line therapy

SUBMITTER: Aluri L 

PROVIDER: S-EPMC12329563 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature